Department of Dermatology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
Department of Dermatology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
J Invest Dermatol. 2021 Feb;141(2):250-252. doi: 10.1016/j.jid.2020.07.010.
Resistance to targeted therapy and immunotherapy remains a major obstacle in improving care for patients with advanced melanoma. MicroRNAs play important roles in regulating gene networks involved in disease progression and resistance to therapy in cancers such as melanoma. MicroRNA miR-211 contributes to melanocyte and melanoma biology and has been implicated in targeted therapy resistance. Lee et al. (2020) report a novel mechanism by which miR-211 promotes resistance to BRAF inhibitor therapy via the upregulation of the extracellular signal-regulated kinase 5 signaling pathway.
靶向治疗和免疫治疗的耐药性仍然是改善晚期黑色素瘤患者治疗效果的主要障碍。microRNAs 在调节癌症（如黑色素瘤）中与疾病进展和治疗耐药性相关的基因网络中发挥重要作用。microRNA miR-211 参与黑素细胞和黑色素瘤的生物学过程，并与靶向治疗耐药性有关。Lee 等人（2020 年）报道了一种新的机制，即 miR-211 通过上调细胞外信号调节激酶 5 信号通路促进 BRAF 抑制剂治疗耐药性。
